
Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

AB Science has revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …

Fresenius has announced its intention to terminate the merger agreement with Akorn, over the $4.75 billion deal that the two …

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …

Researchers working with Professor Martin Fussenegger at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have …

After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border royalties.The …

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

BenevolentAI, a London based drug discovery biotech, has revealed that a $115 million financing round now sees the company valued …

Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …

Merck KGaA has successfully found a buyer for its healthcare unit, after Proctor & Gamble announced that it was prepared …

The first stage of separation for the EMA from the UK came with the decision to relocate its headquarters to …

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …

Frequency Therapeutics is a biotech with big ideas and it has made a big appointment to back up those ideas, …

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …